Pulmonary Arterial Hypertension MarketPulmonary Arterial Hypertension Market By Product Type (Branded and Generics), By Route of Administration (Oral, Intravenous/ Subcutaneous, and Inhalational), By Drug Class (Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin and Prostacyclin Analogs, and PDE-5 Inhibitors), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Published date: March 2025
Report ID: 142618
Number of Pages: 227
Format:

Fact Checked

Cite this Research

- 1. Executive Summary
  - 1.1. Definition
  - 1.2. Market Snapshot
  - 1.3. Market Overview
  - 1.4. Segment Overview
  - 1.5. Regional Overview
  - 1.6. Competitive Landscape
  - 1.7. Taxonomy
- 2. Global Market Overview
  - 2.1. Global Market Insights and Industry Overview
  - 2.2. Market Dynamics
    
    2.2.1. Drivers
    
    2.2.2. Restraints
    
    2.2.3. Opportunities
    
    2.2.4. Key Pulmonary Arterial Hypertension Market Trends
  - 2.3. Regulatory Framework
  - 2.4. Opportunity Map Analysis
  - 2.5. Opportunity Orbits
  - 2.6. PESTLE Analysis
  - 2.7. PORTER’S Five Force Analysis
  - 2.8. Drivers & Restraints Impact Analysis
  - 2.9. Value Chain Analysis
    
    2.9.1. List of Raw Materials Suppliers
    
    2.9.2. List of Pulmonary Arterial Hypertension Manufacturers
    
    2.9.3. List of Dealer/Distributors
  - 2.10. Regional Market Share and BPS Analysis
  - 2.11. Impact of Macro-economic Factors/Geopolitical Factors
- 3. Global Pulmonary Arterial Hypertension Market Analysis and Forecast, By Segment, 2020-2034
  - 3.1. Key Findings
  - 3.2. Global Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
  - 3.3. Global Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
    
    3.3.1. Branded
    
    3.3.1.1. Insights
    
    3.3.1.2. Key Takeaways
    
    3.3.2. Generics
    
    3.3.2.1. Insights
    
    3.3.2.2. Key Takeaways
  - 3.4. Global Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 3.5. Global Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
    
    3.5.1. Oral
    
    3.5.1.1. Insights
    
    3.5.1.2. Key Takeaways
    
    3.5.2. Intravenous/Subcutaneous
    
    3.5.2.1. Insights
    
    3.5.2.2. Key Takeaways
    
    3.5.3. Inhalational
    
    3.5.3.1. Insights
    
    3.5.3.2. Key Takeaways
  - 3.6. Global Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 3.7. Global Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
    
    3.7.1. Prostacyclin and Prostacyclin Analogs
    
    3.7.1.1. Insights
    
    3.7.1.2. Key Takeaways
    
    3.7.2. Endothelin Receptor Antagonists
    
    3.7.2.1. Insights
    
    3.7.2.2. Key Takeaways
    
    3.7.3. SGC Stimulators
    
    3.7.3.1. Insights
    
    3.7.3.2. Key Takeaways
    
    3.7.4. PDE-5 Inhibitors
    
    3.7.4.1. Insights
    
    3.7.4.2. Key Takeaways
- 4. Global Pulmonary Arterial Hypertension Market Analysis and Forecast, By Region, 2020-2034
  - 4.1. Key Findings
  - 4.2. Global Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Region, 2020-2034
    
    4.2.1. North America
    
    4.2.1.1. Regional Insights
    
    4.2.2. Europe
    
    4.2.2.1. Regional Insights
    
    4.2.3. Asia Pacific
    
    4.2.3.1. Regional Insights
    
    4.2.4. Latin America
    
    4.2.4.1. Regional Insights
    
    4.2.5. Middle East & Africa
    
    4.2.5.1. Regional Insights
  - 4.3. Global Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Region
- 5. North America Pulmonary Arterial Hypertension Market Analysis and Forecast, 2020-2034
  - 5.1. Key Findings
  - 5.2. North America Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
  - 5.3. North America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - 5.4. North America Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 5.5. North America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - 5.6. North America Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 5.7. North America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - 5.8. North America Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 5.9. North America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
    
    5.9.1. The US
    
    5.9.2. Canada
- 6. Europe Pulmonary Arterial Hypertension Market Analysis and Forecast, 2020-2034
  - 6.1. Key Findings
  - 6.2. Europe Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
  - 6.3. Europe Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - 6.4. Europe Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 6.5. Europe Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - 6.6. Europe Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 6.7. Europe Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - 6.8. Europe Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 6.9. Europe Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
    
    6.9.1. Germany
    
    6.9.2. The UK
    
    6.9.3. France
    
    6.9.4. Spain
    
    6.9.5. Italy
    
    6.9.6. Russia
    
    6.9.7. Netherland
    
    6.9.8. Rest of Europe
- 7. Asia Pacific Pulmonary Arterial Hypertension Market Analysis and Forecast, 2020-2034
  - 7.1. Key Findings
  - 7.2. Asia Pacific Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
  - 7.3. Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - 7.4. Asia Pacific Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 7.5. Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - 7.6. Asia Pacific Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 7.7. Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - 7.8. Asia Pacific Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 7.9. Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
    
    7.9.1. China
    
    7.9.2. Japan
    
    7.9.3. South Korea
    
    7.9.4. India
    
    7.9.5. Australia
    
    7.9.6. New Zealand
    
    7.9.7. Singapore
    
    7.9.8. Thailand
    
    7.9.9. Vietnam
    
    7.9.10. Rest of Asia Pacific
- 8. Latin America Pulmonary Arterial Hypertension Market Analysis and Forecast, 2020-2034
  - 8.1. Key Findings
  - 8.2. Latin America Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
  - 8.3. Latin America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - 8.4. Latin America Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 8.5. Latin America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - 8.6. Latin America Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 8.7. Latin America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - 8.8. Latin America Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 8.9. Latin America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
    
    8.9.1. Brazil
    
    8.9.2. Mexico
    
    8.9.3. Rest of Latin America
- 9. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis and Forecast, 2020-2034
  - 9.1. Key Findings
  - 9.2. Middle East & Africa Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Product Type, 2020-2034
  - 9.3. Middle East & Africa Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - 9.4. Middle East & Africa Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Route of Administration, 2020-2034
  - 9.5. Middle East & Africa Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - 9.6. Middle East & Africa Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Drug Class, 2020-2034
  - 9.7. Middle East & Africa Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - 9.8. Middle East & Africa Pulmonary Arterial Hypertension Market Size Value (US$ Mn) Analysis, Opportunity and Forecast, By Country, 2020-2034
  - 9.9. Middle East & Africa Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
    
    9.9.1. South Africa
    
    9.9.2. Saudi Arabia
    
    9.9.3. UAE
    
    9.9.4. Rest of Middle East & Africa
- 10. Competitive Landscape & Company Profiles
  - 10.1. Market Competition Scenario Analysis, By Company
    
    10.1.1. Key Takeaways
  - 10.2. Overview of Major Market Players
  - 10.3. Competitor Landscape
  - 10.4. Strategic Mapping
  - 10.5. Company Life Cycle Analysis
  - 10.6. Company Market Share Analysis
  - 10.7. Company Profiles
    
    10.7.1. Viatris Inc
    
    10.7.1.1. Company Details
    
    10.7.1.2. Business Overview
    
    10.7.1.3. Product Portfolio
    
    10.7.1.4. Financial Insights
    
    10.7.1.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.1.6. SWOT Analysis
    
    10.7.1.7. Geographic Footprint
    
    10.7.2. United Therapeutics Corporation
    
    10.7.2.1. Company Details
    
    10.7.2.2. Business Overview
    
    10.7.2.3. Product Portfolio
    
    10.7.2.4. Financial Insights
    
    10.7.2.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.2.6. SWOT Analysis
    
    10.7.2.7. Geographic Footprint
    
    10.7.3. Keros Therapeutics
    
    10.7.3.1. Company Details
    
    10.7.3.2. Business Overview
    
    10.7.3.3. Product Portfolio
    
    10.7.3.4. Financial Insights
    
    10.7.3.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.3.6. SWOT Analysis
    
    10.7.3.7. Geographic Footprint
    
    10.7.4. Johnson & Johnson
    
    10.7.4.1. Company Details
    
    10.7.4.2. Business Overview
    
    10.7.4.3. Product Portfolio
    
    10.7.4.4. Financial Insights
    
    10.7.4.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.4.6. SWOT Analysis
    
    10.7.4.7. Geographic Footprint
    
    10.7.5. Janssen Pharmaceutical Companies
    
    10.7.5.1. Company Details
    
    10.7.5.2. Business Overview
    
    10.7.5.3. Product Portfolio
    
    10.7.5.4. Financial Insights
    
    10.7.5.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.5.6. SWOT Analysis
    
    10.7.5.7. Geographic Footprint
    
    10.7.6. GlaxoSmithKline
    
    10.7.6.1. Company Details
    
    10.7.6.2. Business Overview
    
    10.7.6.3. Product Portfolio
    
    10.7.6.4. Financial Insights
    
    10.7.6.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.6.6. SWOT Analysis
    
    10.7.6.7. Geographic Footprint
    
    10.7.7. Gilead Sciences, Inc
    
    10.7.7.1. Company Details
    
    10.7.7.2. Business Overview
    
    10.7.7.3. Product Portfolio
    
    10.7.7.4. Financial Insights
    
    10.7.7.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.7.6. SWOT Analysis
    
    10.7.7.7. Geographic Footprint
    
    10.7.8. Bayer
    
    10.7.8.1. Company Details
    
    10.7.8.2. Business Overview
    
    10.7.8.3. Product Portfolio
    
    10.7.8.4. Financial Insights
    
    10.7.8.5. Key Developments (Investments & Expansions, Merger & Acquisition, Partnership & Agreement and New Product Development)
    
    10.7.8.6. SWOT Analysis
    
    10.7.8.7. Geographic Footprint
- 11. Methodology and Data Source
  - 11.1. Methodology/Research Approach
  - 11.2. Market Size Estimation
  - 11.3. Market Breakdown and Data Triangulation
  - 11.4. Data Source
  - 11.5. Secondary Sources
  - 11.6. Primary Sources
  - 11.7. Appendix
  - 11.8. Disclaimer
- List of Tables
  - Table 1. Global Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 2. Global Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 3. Global Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 4. Global Pulmonary Arterial Hypertension Market Value (US$ Mn), By Region, 2020-2034
  - Table 5. North America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 6. North America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 7. North America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 8. North America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Country, 2020-2034
  - Table 9. The US Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 10. The US Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 11. The US Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 12. Canada Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 13. Canada Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 14. Canada Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 15. Europe Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 16. Europe Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 17. Europe Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 18. Europe Pulmonary Arterial Hypertension Market Value (US$ Mn), By Country, 2020-2034
  - Table 19. Germany Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 20. Germany Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 21. Germany Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 22. The UK Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 23. The UK Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 24. The UK Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 25. France Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 26. France Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 27. France Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 28. Spain Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 29. Spain Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 30. Spain Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 31. Italy Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 32. Italy Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 33. Italy Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 34. Russia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 35. Russia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 36. Russia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 37. Netherland Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 38. Netherland Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 39. Netherland Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 40. Rest of Europe Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 41. Rest of Europe Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 42. Rest of Europe Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 43. Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 44. Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 45. Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 46. Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Mn), By Country, 2020-2034
  - Table 47. China Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 48. China Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 49. China Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 50. India Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 51. India Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 52. India Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 53. Japan Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 54. Japan Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 55. Japan Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 56. South Korea Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 57. South Korea Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 58. South Korea Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 59. Australia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 60. Australia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 61. Australia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 62. New Zealand Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 63. New Zealand Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 64. New Zealand Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 65. Singapore Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 66. Singapore Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 67. Singapore Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 68. Thailand Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 69. Thailand Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 70. Thailand Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 71. Vietnam Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 72. Vietnam Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 73. Vietnam Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 74. Rest of Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 75. Rest of Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 76. Rest of Asia Pacific Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 77. Latin America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 78. Latin America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 79. Latin America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 80. Latin America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Country, 2020-2034
  - Table 81. Brazil Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 82. Brazil Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 83. Brazil Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 84. Mexico Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 85. Mexico Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 86. Mexico Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 87. Rest of Latin America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 88. Rest of Latin America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 89. Rest of Latin America Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 90. Middle East & Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 91. Middle East & Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 92. Middle East & Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 93. Middle East & Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Country, 2020-2034
  - Table 94. South Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 95. South Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 96. South Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 97. Saudi Arabia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 98. Saudi Arabia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 99. Saudi Arabia Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 100. UAE Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 101. UAE Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 102. UAE Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
  - Table 103. Rest of Middle East & Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Product Type, 2020-2034
  - Table 104. Rest of Middle East & Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Route of Administration, 2020-2034
  - Table 105. Rest of Middle East & Africa Pulmonary Arterial Hypertension Market Value (US$ Mn), By Drug Class, 2020-2034
- List of Figures
  - Figure 1. Global Pulmonary Arterial Hypertension Market Snapshot: Market Value (US$ Mn), 2020-2034
  - Figure 2. Opportunity Map
  - Figure 3. Opportunity Orbit
  - Figure 4. Regional Market Share and BPS Analysis in Pulmonary Arterial Hypertension Market
  - Figure 5. Global Pulmonary Arterial Hypertension Market Analysis, By Product Type, 2020, 2024 and 2034
  - Figure 6. Global Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - Figure 7. Global Pulmonary Arterial Hypertension Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 8. Global Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - Figure 9. Global Pulmonary Arterial Hypertension Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 10. Global Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - Figure 11. Global Pulmonary Arterial Hypertension Market Analysis, By Region, 2020, 2024 and 2034
  - Figure 12. Global Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Region
  - Figure 13. North America Pulmonary Arterial Hypertension Market Analysis, By Product Type, 2020, 2024 and 2034
  - Figure 14. North America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - Figure 15. North America Pulmonary Arterial Hypertension Market (US$ Mn), by Branded, 2020-2034
  - Figure 16. North America Pulmonary Arterial Hypertension Market (US$ Mn), by Generics, 2020-2034
  - Figure 17. North America Pulmonary Arterial Hypertension Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 18. North America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - Figure 19. North America Pulmonary Arterial Hypertension Market (US$ Mn), by Oral, 2020-2034
  - Figure 20. North America Pulmonary Arterial Hypertension Market (US$ Mn), by Intravenous/Subcutaneous, 2020-2034
  - Figure 21. North America Pulmonary Arterial Hypertension Market (US$ Mn), by Inhalational, 2020-2034
  - Figure 22. North America Pulmonary Arterial Hypertension Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 23. North America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - Figure 24. North America Pulmonary Arterial Hypertension Market (US$ Mn), by Prostacyclin and Prostacyclin Analogs, 2020-2034
  - Figure 25. North America Pulmonary Arterial Hypertension Market (US$ Mn), by Endothelin Receptor Antagonists, 2020-2034
  - Figure 26. North America Pulmonary Arterial Hypertension Market (US$ Mn), by SGC Stimulators, 2020-2034
  - Figure 27. North America Pulmonary Arterial Hypertension Market (US$ Mn), by PDE-5 Inhibitors, 2020-2034
  - Figure 28. North America Pulmonary Arterial Hypertension Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 29. North America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
  - Figure 30. Europe Pulmonary Arterial Hypertension Market Analysis, By Product Type, 2020, 2024 and 2034
  - Figure 31. Europe Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - Figure 32. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by Branded, 2020-2034
  - Figure 33. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by Generics, 2020-2034
  - Figure 34. Europe Pulmonary Arterial Hypertension Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 35. Europe Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - Figure 36. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by Oral, 2020-2034
  - Figure 37. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by Intravenous/Subcutaneous, 2020-2034
  - Figure 38. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by Inhalational, 2020-2034
  - Figure 39. Europe Pulmonary Arterial Hypertension Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 40. Europe Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - Figure 41. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by Prostacyclin and Prostacyclin Analogs, 2020-2034
  - Figure 42. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by Endothelin Receptor Antagonists, 2020-2034
  - Figure 43. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by SGC Stimulators, 2020-2034
  - Figure 44. Europe Pulmonary Arterial Hypertension Market (US$ Mn), by PDE-5 Inhibitors, 2020-2034
  - Figure 45. Europe Pulmonary Arterial Hypertension Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 46. Europe Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
  - Figure 47. Asia Pacific Pulmonary Arterial Hypertension Market Analysis, By Product Type, 2020, 2024 and 2034
  - Figure 48. Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - Figure 49. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by Branded, 2020-2034
  - Figure 50. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by Generics, 2020-2034
  - Figure 51. Asia Pacific Pulmonary Arterial Hypertension Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 52. Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - Figure 53. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by Oral, 2020-2034
  - Figure 54. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by Intravenous/Subcutaneous, 2020-2034
  - Figure 55. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by Inhalational, 2020-2034
  - Figure 56. Asia Pacific Pulmonary Arterial Hypertension Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 57. Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - Figure 58. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by Prostacyclin and Prostacyclin Analogs, 2020-2034
  - Figure 59. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by Endothelin Receptor Antagonists, 2020-2034
  - Figure 60. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by SGC Stimulators, 2020-2034
  - Figure 61. Asia Pacific Pulmonary Arterial Hypertension Market (US$ Mn), by PDE-5 Inhibitors, 2020-2034
  - Figure 62. Asia Pacific Pulmonary Arterial Hypertension Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 63. Asia Pacific Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
  - Figure 64. Latin America Pulmonary Arterial Hypertension Market Analysis, By Product Type, 2020, 2024 and 2034
  - Figure 65. Latin America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - Figure 66. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by Branded, 2020-2034
  - Figure 67. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by Generics, 2020-2034
  - Figure 68. Latin America Pulmonary Arterial Hypertension Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 69. Latin America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - Figure 70. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by Oral, 2020-2034
  - Figure 71. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by Intravenous/Subcutaneous, 2020-2034
  - Figure 72. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by Inhalational, 2020-2034
  - Figure 73. Latin America Pulmonary Arterial Hypertension Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 74. Latin America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - Figure 75. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by Prostacyclin and Prostacyclin Analogs, 2020-2034
  - Figure 76. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by Endothelin Receptor Antagonists, 2020-2034
  - Figure 77. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by SGC Stimulators, 2020-2034
  - Figure 78. Latin America Pulmonary Arterial Hypertension Market (US$ Mn), by PDE-5 Inhibitors, 2020-2034
  - Figure 79. Latin America Pulmonary Arterial Hypertension Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 80. Latin America Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
  - Figure 81. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis, By Product Type, 2020, 2024 and 2034
  - Figure 82. Middle East & Africa Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Product Type
  - Figure 83. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by Branded, 2020-2034
  - Figure 84. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by Generics, 2020-2034
  - Figure 85. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis, By Route of Administration, 2020, 2024 and 2034
  - Figure 86. Middle East & Africa Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Route of Administration
  - Figure 87. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by Oral, 2020-2034
  - Figure 88. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by Intravenous/Subcutaneous, 2020-2034
  - Figure 89. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by Inhalational, 2020-2034
  - Figure 90. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis, By Drug Class, 2020, 2024 and 2034
  - Figure 91. Middle East & Africa Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Drug Class
  - Figure 92. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by Prostacyclin and Prostacyclin Analogs, 2020-2034
  - Figure 93. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by Endothelin Receptor Antagonists, 2020-2034
  - Figure 94. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by SGC Stimulators, 2020-2034
  - Figure 95. Middle East & Africa Pulmonary Arterial Hypertension Market (US$ Mn), by PDE-5 Inhibitors, 2020-2034
  - Figure 96. Middle East & Africa Pulmonary Arterial Hypertension Market Analysis, By Country, 2020, 2024 and 2034
  - Figure 97. Middle East & Africa Pulmonary Arterial Hypertension Market Attractiveness Analysis, By Country
- Viatris Inc
- United Therapeutics Corporation
- Keros Therapeutics
- Johnson & Johnson
- Janssen Pharmaceutical Companies
- GlaxoSmithKline
- Gilead Sciences, Inc
- Bayer